Orforglipron Research for Type 2 Diabetes
An evidence-based overview of research examining Orforglipron in the context of type 2 diabetes. This page synthesizes findings from peer-reviewed literature.
Research Summary
ATTAIN-2 evaluated orforglipron in adults with obesity and type 2 diabetes, showing statistically significant improvements in HbA1c and all prespecified weight and cardiometabolic measures with the 36mg dose vs placebo at 72 weeks. The oral administration without food restrictions offers practical advantages over existing therapies.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Orforglipron may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.